– Sulanda® is Chi-Med's first oncology drug brought to market without a partnership and the company's second oncology drug approved in China – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS in all subgroups of non-pancreatic NET patients with an acceptable risk/benefit ratio – – ~400-strong oncology commercial team in place to...
Read Full StoryRelated
, 11min
0
Disease-prevention-and-treatment
Plan needed to cope with indefinite international border closures
, 13min
0
, 21min
0
, 23min
0